Micro-Tech Nanjing Co Ltd
SSE:688029
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
56.6
98.82
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Micro-Tech Nanjing Co Ltd
Cash from Financing Activities
Micro-Tech Nanjing Co Ltd
Cash from Financing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
M
|
Micro-Tech Nanjing Co Ltd
SSE:688029
|
Cash from Financing Activities
-¥114.5m
|
CAGR 3-Years
-30%
|
CAGR 5-Years
-89%
|
CAGR 10-Years
N/A
|
|
|
Shandong Weigao Group Medical Polymer Co Ltd
HKEX:1066
|
Cash from Financing Activities
-¥1.2B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Autobio Diagnostics Co Ltd
SSE:603658
|
Cash from Financing Activities
-¥1.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-60%
|
CAGR 10-Years
N/A
|
|
|
Winner Medical Co Ltd
SZSE:300888
|
Cash from Financing Activities
-¥1.8B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
Cash from Financing Activities
-¥568.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-41%
|
CAGR 10-Years
N/A
|
|
|
Intco Medical Technology Co Ltd
SZSE:300677
|
Cash from Financing Activities
¥2B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
41%
|
CAGR 10-Years
N/A
|
|
Micro-Tech Nanjing Co Ltd
Glance View
Micro-Tech (Nanjing) Co., Ltd. engages in the manufacture of medical equipment. The company is headquartered in Nanjing, Jiangsu and currently employs 2,315 full-time employees. The company went IPO on 2019-07-22. The firm's main products include three series of endoscopic diagnosis and treatment instruments used with endoscopes, microwave ablation equipment and consumables, and disposable endoscopes. Endoscopic diagnosis and treatment equipment mainly includes biopsy, hemostasis and closure, Endoscopic Mucosal Resection (EMR)/Endoscopic Submucosal Dissection (ESD), dilation, and Endoscopic Retrograde Cholangiopancreatography (ERCP), Endoscopic Ultrasonography (EUS) and Endobronchial Ultrasound (EBUS) products. Microwave ablation mainly includes microwave ablation instrument and microwave ablation needle series products. Disposable endoscope mainly includes disposable biliopancreatic imaging system (choledochoscope) and related consumables and other products.
See Also
What is Micro-Tech Nanjing Co Ltd's Cash from Financing Activities?
Cash from Financing Activities
-114.5m
CNY
Based on the financial report for Dec 31, 2023, Micro-Tech Nanjing Co Ltd's Cash from Financing Activities amounts to -114.5m CNY.
What is Micro-Tech Nanjing Co Ltd's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
-89%
Over the last year, the Cash from Financing Activities growth was -55%. The average annual Cash from Financing Activities growth rates for Micro-Tech Nanjing Co Ltd have been -30% over the past three years , -89% over the past five years .
You don't have any saved screeners yet
